Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Eugene Komchuk
Eugene Komchuk

INOVIO Pharmaceuticals to release third quarter financial results on November 10

INOVIO Pharmaceuticals to release third quarter financial results on November 10
INOVIO Pharmaceuticals sets Q3 results date

INOVIO Pharmaceuticals announced it will report its third quarter 2026 financial results on Tuesday, November 10 after market close.

The company will host a conference call at 4:30 p.m. ET to review the results and present a business update. A live webcast and replay will be accessible through the company's website.

Earlier this year, INOVIO Pharmaceuticals secured FDA accelerated approval for its DNA-based immunotherapy designed to reduce surgeries in recurrent respiratory papillomatosis, according to a previous report here. The approval marked a significant regulatory milestone for the company. INOVIO continues to advance its pipeline of DNA medicines in clinical development.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Tom Lee’s Ethereum bet: Why he expects another crypto boom
  • By Mikhail Vnuchkov
  • 2 hours ago
Tom Lee’s Ethereum bet: Why he expects another crypto boom
Editors' Picks
How Paul McCartney became a billionaire and the role the stock market played
  • By Eugene Komchuk
  • 5 hours ago
How Paul McCartney became a billionaire and the role the stock market played
Editors' Picks
Buterin’s new vision: Why Ethereum wants to become digital gold
  • By Olena Litvinenko
  • Yesterday
Buterin’s new vision: Why Ethereum wants to become digital gold
Editors' Picks
All Editors' Top Picks

Latest Inovio News

FDA approves INOVIO Pharmaceuticals DNA-based treatment to reduce surgery need in RRP
  • By Hanna Syniavska
  • 31.10.2026
FDA approves INOVIO Pharmaceuticals DNA-based treatment to reduce surgery need in RRP
Companies
#Inovio
INOVIO Pharmaceuticals to join investor conferences with webcast presentations and meetings
  • By Ksenia Gerey
  • 02.09.2026
INOVIO Pharmaceuticals to join investor conferences with webcast presentations and meetings
Companies
#Inovio
Second quarter 2026 earnings and operations update released by INOVIO Pharmaceuticals
  • By Andrey Mastykin
  • 12.08.2026
Second quarter 2026 earnings and operations update released by INOVIO Pharmaceuticals
Companies
#Inovio
All Inovio News
  • Mikhail Vnuchkov
  • 2 hours ago
Tom Lee’s Ethereum bet: Why he expects another crypto boom
  • Eugene Komchuk
  • 5 hours ago
How Paul McCartney became a billionaire and the role the stock market played
  • Olena Litvinenko
  • Yesterday
Buterin’s new vision: Why Ethereum wants to become digital gold
  • Anastasiia Chabaniuk
  • Yesterday
From affair to market crash: How the Nvidia scandal hit Bitcoin
  • Dmytro Kharkov
  • Yesterday
Shield AI’s Echodyne deal and the global counter-drone race
  • Yulia Slavina
  • 9 min ago
Inflation data rises more than forecast, Justin Wolfers notes
  • Hanna Syniavska
  • 14 min ago
Amit Kukreja: October U.S. CPI exceeds expectations with 0.4 percent increase
  • Daria Chernytska
  • 14 min ago
Bitcoin moves closer to $74K after Fed governor Waller supports December hike, Crypto Briefing notes
  • Mikhail Vnuchkov
  • 17 min ago
Average U.S. gas price falls to $3.97 today, AAA notes
  • Igor Krasulya
  • 17 min ago
Ben Casselman: U.S. consumer prices rose 0.4% in October
Top News
  • Hanna Syniavska
  • 1 hour ago
U.S. stock futures trade mixed ahead of crucial inflation report
U.S. stock futures trade mixed ahead of crucial inflation report
  • Igor Krasulya
  • 3 hours ago
Fed Governor Waller warns inflation could justify 50-basis-point rate hike
Fed Governor Waller warns inflation could justify 50-basis-point rate hike
  • Ivan Andriyenko
  • 3 hours ago
Gold prices retreat as December Fed rate hike looms
Gold prices retreat as December Fed rate hike looms
  • Pavlo Kot
  • 5 hours ago
Nvidia shareholders sue company over CEO Jensen Huang scandal
Nvidia shareholders sue company over CEO Jensen Huang scandal
  • Andrey Mastykin
  • 5 hours ago
Anthropic pulls nearly $70 billion IPO plan ahead of investor roadshow
Anthropic pulls nearly $70 billion IPO plan ahead of investor roadshow
Live News
  • Kyle Torpey
  • Now
Binance hackers launder stolen funds through Elon Musk-themed memecoins
  • Mykhailo Ihnatenko
  • Now
Intel stock forecast: Can CPI volatility derail the rebound toward 70?
  • Jose Antonio Gastelum
  • Now
Polymarket widens lead over Kalshi in political prediction markets
  • Anton Kharitonov
  • Now
EUR/USD holds above 1.1200 as traders await U.S. inflation data
  • Eugene Komchuk
  • Now
BitGo revenue halves amid crypto trading slowdown
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers